Dynamis Skin Science is a division of Dynamis Therapeutics, Inc., an early stage pharmaceutical company. Dynamis Therapeutics was founded in 1997 by a team of scientists as a joint venture between Fox Chase Cancer Center (FCCC) in Philadelphia and a group of investors. It was originally funded by the Ben Franklin Technology Center, the National Institutes of Health as well as venture capital. The company scientists originally focused on the discovery and development of therapeutic pharmaceuticals to treat and prevent diabetic complications resulting from glucose induced glycation and oxidative stress.
While conducting research on a novel technology that could improve the lives of cancer patients and diabetics, a team of scientists at the Fox Chase Cancer Center in Philadelphia, Pennsylvania discovered the presence of 3-deoxyglucosone (3DG) in skin. The NIH-funded research uncovered the link between 3DG (3-deoxyglucosone) and collagen depletion, loss of skin elasticity, leading to skin aging. The Fox Chase scientists then discovered how to control 3DG through the discovery of Supplamine, a powerful new formulation to antagonize the effects of 3DG's glycation and oxidative stress on skin. Thus the creation of MEG21 moisturizing, aging skin and anti-wrinkle products began.
Attention: MEG 21 products cannot be shipped outside of the United States